April 2020 HSC Section 4 - Plastic and Reconstructive Problems

G LOGAU E T A L

outcomes, and decision to have treatment: development and validation. Plast Reconstr Surg 2015;135:375 – 86. 17. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 2008;59:565 – 90. 18. Walker P, Lee D, Toth BA. A histological analysis of the effects of single doses of ATX-101 on subcutaneous fat: results from a phase 1 open-label safety study of ATX-101. Presented at the American Society for Dermatologic Surgery Annual Meeting, October 3 – 6, 2013; Chicago, IL. 19. Beer K, Weinkle SH, Cox SE, Rubin MG, et al. ATX-101 (deoxycholic acid injection) for reduction of submental fat: results from a 12-month open-label study. Unpublished data. 20. Bhatia AC, Dayan SH, Hoffmann K, et al. Reductions in submental fat achieved with deoxycholic acid injection (ATX-101) are maintained over time: results from long-term, follow-up studies. Presented at the Annual Meeting of the American Society for Dermatologic Surgery, October 15 – 18, 2015; Chicago, IL. 21. Dover JS, Shridharani SM, Bloom JD, Somogyi C, et al. Reduction of submental fat continues beyond 28 days after ATX-101 treatment: results from a post hoc analysis. Dermatol Surg 2018;44: 1477 – 79.

10. Rzany B, Grif fi ths T, Walker P, Lippert S, et al. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol 2014;170: 445 – 53. 11. Kybella (Deoxycholic Acid) Injection [prescribing information] . Westlake Village, CA: Kythera Biopharmaceuticals, Inc.; 2015. Available from: https://www.allergan.com/assets/pdf/kybella_pi. Accessed March 1, 2018. 12. Belkyra (Deoxycholic Acid Injection) [product Monograph] . Markham, ON: Allergan Inc.; 2016. Available from: http:// allergan-web-cdn-prod.azureedge. net/allergancanadaspecialty/allergancanadaspecialty/media/actavis- canada-specialty/en/products/pms/belkyra-pm-2016-03-28_e.pdf. Accessed March 1, 2018. 13. Gross TM, Burgess SM, Somogyi C, Lizzul PF, et al. Development and validation of a patient-reported outcome measure of the psychological impact of submental fat. Value Health 2015;18:A412. 14. Klassen AF, Cano SJ, Scott A, Snell L, et al. Measuring patient-reported outcomes in facial aesthetic patients: development of the FACE-Q. Facial Plast Surg 2010;26:303 – 9. 15. Pusic AL, Klassen AF, Scott AM, Cano SJ. Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clin Plast Surg 2013;40:249 – 60. 16. Klassen AF, Cano SJ, Schwitzer JA, Scott AM, et al. FACE-Q scales for health-related quality of life, early life impact, satisfaction with

Address correspondence and reprint requests to: Richard Glogau, MD, 350 Parnassus Avenue, Suite 400, San Francisco, CA 94117, or e-mail: rglogau@sfderm.com

0 0 : 0 0 : MONTH 2 0 1 9

69